The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
- PMID: 27856683
- PMCID: PMC5549781
- DOI: 10.1177/0269881116678781
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Abstract
Acute adverse psychological reactions to classic hallucinogens ("bad trips" or "challenging experiences"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms. Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire. The stand-alone Challenging Experience Questionnaire was then validated in a separate sample. Seven Challenging Experience Questionnaire factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) provide a phenomenological profile of challenging aspects of experiences with psilocybin. Factor scores were associated with difficulty, meaningfulness, spiritual significance, and change in well-being attributed to the challenging experiences. The factor structure did not differ based on gender or prior struggle with anxiety or depression. The Challenging Experience Questionnaire provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.
Keywords: Psilocybin; challenging experiences; factor analysis; psychedelics; scale development.
© The Author(s) 2016.
Conflict of interest statement
RRG is a member of the Board of Directors of the Heffter Research Institute.
References
-
- Abramson HA. Lysergic acid diethylamide (LSD-25). XXXI. comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. The Journal of Mental Science. 1960;106:1120–1123. - PubMed
-
- Belleville RE. MMPI score changes induced by lysergic acid diethylamide (LSD-25) Journal of Clinical Psychology. 1956;12(3):279–282. - PubMed
-
- Bentler PM. Comparative fit indexes in structural models. Psychological Bulletin. 1990;107(2):238–246. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
